RxDoctor Payments Data

James Moghtader, MD

Psychiatry · Santa Barbara, CANPI 1568475424

Payments from drug & device makers

$36,972in general payments, 2019–2025

Across 426 payments — averaging $86.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$27K
  • Sunovion Pharmaceuticals Inc.$6K
  • Neurocrine Biosciences, Inc.$750
  • Takeda Pharmaceuticals U.S.A., Inc.$423
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$328
  • Otsuka America Pharmaceutical, Inc.$323
  • plus $3K from 16 others

What the payments were for

  • Speaking & faculty fees$28,49977%
  • Travel & lodging$9082%
  • Food & beverage$7,35620%
  • Education$2091%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,972 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$153,670
Medicare patients
231
Services billed
1,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$290,109
AustedoDeutetrabenazine20$150,855
VraylarCariprazine Hcl24$45,720
Lurasidone Hcl66$33,662
CaplytaLumateperone Tosylate16$29,107
TrintellixVortioxetine Hydrobromide23$17,125
Desvenlafaxine Succinate ErDesvenlafaxine Succinate119$7,323
CymbaltaDuloxetine Hcl11$5,951
VyvanseLisdexamfetamine Dimesylate11$5,762
Aripiprazole136$5,511
Venlafaxine Hcl ErVenlafaxine Hcl201$5,394
Quetiapine Fumarate201$5,324
Bupropion XlBupropion Hcl179$5,186
BelsomraSuvorexant11$4,785
Wellbutrin SrBupropion Hcl11$4,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$750$290,10923 claims
Teva Pharmaceuticals USA, Inc.Austedo$279$150,85520 claims
AbbVieVraylar$26,762$45,72024 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$328$29,10716 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$423$22,88734 claims
MerckBelsomra$104$4,78511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →